Mr Market is far smarter and infinitely more experienced than average HC punter.
CUV holders seem totally incapable of understanding that orphan drugs (<200,000 patients) - like Scenesse - have much lower regulatory standards than normal. So existing FDA, TGA etc approval for EPP actually means very little.
The market simply doesn't believe the hype about new indications. Fifty years of research on alpha-melanocortin analogues has only produced two obscure orphan drugs and massive number of failures. Virtually ever other drug has has failed Phase I or Phase 2 trials.
CUV Price at posting:
$16.29 Sentiment: None Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)